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NADþ protects against EAE by regulating CD4þ
T-cell differentiation
Stefan G. Tullius1,*, Hector Rodriguez Cetina Biefer1,2,*, Suyan Li3, Alexander J. Trachtenberg4, Karoline Edtinger1,
Markus Quante1, Felix Krenzien1, Hirofumi Uehara1, Xiaoyong Yang1, Haydn T. Kissick5, Winston P. Kuo4,
Ionita Ghiran6, Miguel A. de la Fuente7, Mohamed S. Arredouani5, Virginia Camacho8, John C. Tigges8,
Vasilis Toxavidis8, Rachid El Fatimy9, Brian D. Smith10, Anju Vasudevan3 & Abdallah ElKhal1
CD4þ Tcells are involved in the development of autoimmunity, including multiple sclerosis
(MS). Here we show that nicotinamide adenine dinucleotide (NADþ) blocks experimental
autoimmune encephalomyelitis (EAE), a mouse model of MS, by inducing immune
homeostasis through CD4þIFNgþIL-10þ T cells and reverses disease progression by
restoring tissue integrity via remyelination and neuroregeneration. We show that
NADþ regulates CD4þ T-cell differentiation through tryptophan hydroxylase-1 (Tph1),
independently of well-established transcription factors. In the presence of NADþ, the
frequency of T-bet /  CD4þIFNgþ Tcells was twofold higher than wild-type CD4þ Tcells
cultured in conventional T helper 1 polarizing conditions. Our ﬁndings unravel a new pathway
orchestrating CD4þ T-cell differentiation and demonstrate that NADþ may serve as a
powerful therapeutic agent for the treatment of autoimmune and other diseases.
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D4þ T helper (Th) cells play a central role in regulating
the adaptive immune response associated with pathogen
invasion. To date, several CD4þ Th cell subsets have been
described. Th1 and Th2 subsets were the ﬁrst described1–4,
whereas Th17 and induced regulatory T cells were characterized
more recently5–7. Each distinct CD4þ T-cell subset has a speciﬁc
function and can mainly be distinguished by its cytokine proﬁle,
the expression pattern of cell surface molecules, and the
activation of speciﬁc transcription factors8. However, the
function of CD4þ T cells can be impaired resulting in
numerous diseases, including allergic responses, tumour
immunity and autoimmunity9,10. In multiple sclerosis (MS),
Th1 and Th17 subsets have been shown to play a central role11.
MS is an inﬂammatory-mediated demyelinating disease that has
been associated with production of interferon (IFN)-g and
interleukin (IL)-17, two cytokines that are produced by Th1
and Th17 cells, respectively12. More recently, the role of Th1
and Th17 CD4þ cells in the pathogenesis of experimental
autoimmune encephalomyelitis (EAE), the most commonly used
experimental model for human MS, has been challenged, and it
has been demonstrated that the transcription factor T-bet
(also known as Tbx21) is critical for controlling Th1/Th17-
mediated autoimmunity12. In contrast, regulatory T cells (Tregs)
play a cardinal role in protecting against autoimmune diseases,
inﬂammation and tissue damage13 through secretion of IL-10
(ref. 14) and other mechanisms. Although differentiation of naı ¨ve
CD4þ T cells has been considered to be an irreversible process,
accumulating evidence suggests that T cells are much more
ﬂexible than initially believed with the ability to interchange
between helper phenotypes15. For instance, Th17 cells are able to
co-produce IFN-g, initially considered exclusively a Th1
cytokine16,17. It has been shown that Th17 cells can also co-
express Foxp3 or T-bet18–19, which are the master regulators of
Tregs and Th1 cells, respectively. Moreover, Th1 IFN-g-
producing cells have been shown to have the capacity to
produce the immunosuppressive cytokine IL-10, initially
considered a Th2 cytokine20. Studies have shown that Th1 IFN-
g-producing cells that co-produce IL-10 have immunosuppressive
properties and can protect from tissue damage21,22. In addition, it
was recently shown that Th17 cells that were generated with
transforming growth factor (TGF)-b and IL-6 were not
pathogenic and did not induce EAE without exposure to IL-23
(ref. 23). Thus, these reports suggest the existence of broad
plasticity of Th1 and Th17 cells.
In EAE, it was reported that nicotinamide (Nam), a precursor
of nicotinamide adenine dinucleotide (NADþ) biosynthesis,
plays an important role in the disease. This study reported that
Nam reduced CD4þ T cell inﬁltration and demyelination24, but
failed to identify the protective mechanisms of action. In contrast,
a different study found that inhibition of NADþ synthesis by
FK866, an inhibitor of nicotinamide phosphoribosyltransferase
(Nampt), protected against EAE25. In this latter study, it was
reported that FK866 treatment was associated with a massive
depletion of NADþ in activated CD3þ T lymphocytes and
impaired their proliferation and cytokine production25.
Furthermore, numerous studies have underscored the role of
NADþ, a co-factor found in all living cells and in nutrients, in
T-cell regulation. In vivo, NADþ has been shown to induce
apoptosis in naı ¨ve CD4þCD62Lhigh T cells and Foxp3þ
regulatory T cells26,27. Conversely, activated CD44highCD69high
T cells were more resistant to NADþ-induced cell death26.
Moreover, it was reported that NADþ regulates cytokine
production of peripheral blood lymphocytes and monocytes25,28.
These studies provided a strong rationale to investigate the role
of NADþ in CD4þ T cells and its impact on EAE. Here we show
that administration of NADþ protects against EAE and reverses
disease progression by regulating CD4þ T-cell differentiation
and apoptosis through a novel signalling pathway and by
promoting myelin and axonal regeneration.
Results
NADþ restores tissue integrity and induces homeostasis.
Increasing evidence indicates that NADþ may play an active role
in protecting against EAE24,29. Consequently, we used the widely
utilized EAE mouse model that recapitulates human MS, to study
the impact of NADþ on EAE. Our results showed that onset of
clinical signs of EAE in mice injected with myelin
olygodendrocyte glycoprotein (MOG) peptide occurred after 11
days, and severe EAE was exhibited after 18 days with bilateral
hindlimb paralysis (Fig. 1a and Supplementary Movie 1a and 1b).
In contrast, mice treated daily with NADþ were protected
against EAE and exhibited no signs of paralysis (Fig. 1a and
Supplementary Movie 1c). Moreover, NADþ-treated mice did
not develop EAE even after 25 days (Fig. 1a and Supplementary
Movie 1f), whereas non-treated mice exhibited severe symptoms
(Fig. 1a and Supplementary Movie 1d). Furthermore, to assess the
clinical efﬁcacy of NADþ and its therapeutic potential, a group
of mice that had developed severe clinical symptoms of EAE (that
is, bilateral hindlimb paralysis) was subjected to daily NADþ
treatment starting 15 days after MOG immunization. As shown
in Fig. 1a and Supplementary Movie 1e, daily treatment with
NADþ starting 15 days after MOG immunization reversed the
progression of the disease when compared with the group of mice
that had been treated with a placebo solution (Fig. 1a and
Supplementary Movie 1d and e). Treatment with NADþ starting
15 days after MOG immunization rapidly resolved (within 10
days of treatment) the bilateral hindlimb paralysis, whereas a
majority of the non-treated mice continued to exhibit bilateral
hindlimb paralysis or weakness (Fig. 1a and Supplementary
Movie 1d and 1e). Taken together, these results indicate that
NADþ treatment is not only able to block EAE progression, but
Figure 1 | NADþ prevents demyelination and axon loss. (a) Behavioural scores of EAE in C57BL/6 mice treated at the day of MOG immunization daily
with intraperitoneal injection of 60mg of NADþ or a placebo solution (PBS). An additional group of mice was treated with intraperitoneal injection of
60mg of NADþ 15 days after MOG immunization (n¼8–11 per group). (b–i) Myelin and neuroﬁlament (NF) assessment in spinal cord of: (b) mice
that were treated daily with a placebo solution (PBS), (c) mice that were treated daily with NADþ and (d) mice that were treated with NADþ 15 days after
MOG immunization (when mice developed hindlimb paralysis). (b–d) Parafﬁn sections were stained with luxol fast blue (LFB) to assess demyelination,
H&E for lymphocyte inﬁltration, myelin basic protein (MBP) to assess demyelination, NF 200 for axon loss and DAPI to label nuclei. Merged images of
MBP, NF and DAPI are also shown. The boxed regions in a–c for LFB and H&E staining have been magniﬁed in d–f, respectively. The white stars in a–c for
MBP, NF, DAPI and merged images depict regions that are shown in higher magniﬁcation in d–f. Scale bars: a, 100mm (applies to b–d), d,5 0mm (applies to
e–g). (h,i) Quantiﬁcation of myelination and NF-positive areas showing a signiﬁcant protection and recovery of (h) myelin and (i) NFs following daily
NADþ treatment and administration 15 days after MOG immunization. (j,k) Vimentin/Ki67 (j) and Vimentin/Musashi (k) co-labelling revealed increased
ependymal cell proliferation in NADþ-treated spinal cord when compared with PBS-treated spinal cord. Scale bars: (b), 100mm (applies to c,d); (e), 50mm
(applies to f,g); (j), 20mm (applies to k); n¼8–11; data derived from three independent experiments. Data represent mean±s.d. *Po0.05; **Po0.01;
***Po0.001, NS, not signiﬁcant. Student’s t-test and Mann–Whitney U-test were used accordingly to compare between groups.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6101
2 NATURE COMMUNICATIONS|5:5101|DOI: 10.1038/ncomms6101|www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
NAD
+
NAD
+
1,750,000
LFB
PBS -
treated
NAD+ -
treated
PBS -
treated
NAD+ -
treated
Vimentin + Ki67
Vimentin + Musashi
Neurofilament
***
***
***
***
0
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
250,000
500,000
750,000
1,000,000
1,250,000
1,500,000
MOG
MOG + NAD+ at day 1 post-immunization
MOG + NAD+ at day 15 post-immunization
MOG
MOG + NAD+
MOG + late NAD+
E
A
E
 
s
c
o
r
e
********
**
************ ********
**
*
*
Days post-immunization
PBS -treated
LFB
H&E
MBP
NF
DAPI
Merged
H&E
MBP
NF
DAPI
Merged
H&E
MBP
NF
DAPI
Merged
H&E
MBP
NF
DAPI
Merged
H&E
MBP
NF
DAPI
Merged
H&E
MBP
NF
DAPI
Merged
* *
*
* *
* *
*
* * *
LFB LFB LFB LFB LFB
NAD+ -treated NAD+ late -treated PBS -treated NAD+ -treated NAD+ late-treated
0
1
2
3
4
5
6
7
8
9
1
0
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
2
1
2
2
2
3
2
4
2
5
2
6
I
n
t
e
g
r
a
t
e
d
 
o
p
t
i
c
a
l
d
e
n
s
i
t
y
 
(
I
O
D
)
I
n
t
e
g
r
a
t
e
d
 
o
p
t
i
c
a
l
d
e
n
s
i
t
y
 
(
I
O
D
)
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6101 ARTICLE
NATURE COMMUNICATIONS|5:5101|DOI: 10.1038/ncomms6101|www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.can also rapidly reverse it. Thus, we next investigated how
NADþ treatment was able to arrest and reverse EAE progression
and assessed whether NADþ was able to reverse the clinical
symptoms of EAE by protecting axons from degeneration and
whether NADþ had the capacity to promote myelin
regeneration. Luxol fast blue (LFB) staining showed dramatic
myelin loss, and haematoxylin and eosin (H&E) staining revealed
extensive inﬂammatory inﬁltrates of mononuclear cells in the
spinal cords of mice treated with a placebo solution (Fig. 1b,e). In
contrast, the spinal cords of mice treated daily with NADþ
remained free of myelin loss and inﬂammatory inﬁltrates
(Fig. 1c,f) in LFB and H&E staining. More importantly, the
spinal cords of mice treated with NADþ starting 15 days after
MOG immunization (that is, treated after hindlimb paralysis) did
not show myelin loss and inﬂammatory inﬁltrate (Fig. 1d,g) in
LFB and H&E staining. In addition, demyelination and axon loss
were assessed with antibodies to myelin basic protein (MBP/SMI-
9) and neuroﬁlament (NF) 200, respectively, in all three groups
(Fig. 1b–g). Consistent with H&E and LFB ﬁndings, a signiﬁcant
reduction in both MBP staining depicting demyelination and
axon loss evidenced by reduced NF 200 staining was very
prominent in the group of mice treated with a placebo solution
(Fig. 1b,e) when compared with the daily NADþ-treated group
(Fig. 1c,f) and with mice treated with NADþ after developing
hindlimb paralysis (15 days after MOG immunization; Fig. 1d,g).
Furthermore, areas and degree of demyelination and axon loss
were quantiﬁed in mice treated with placebo solution and the
group of mice treated with NADþ daily or 15 days after MOG
immunization (Fig. 1h,i). The results indicated a higher optical
density of LFB and NF immunoﬂuorescence in the two groups of
NADþ-treated mice when compared with the control group
(Fig. 1h,i). Of note, optical density of LFB immunostaining was
more pronounced in the group of mice treated with NADþ daily
when compared with the late-treated group; this was less
pronounced in the NF immunoﬂuorescence (Fig. 1h,i). A recent
study has shown that NADþ precursor Nam) plays an important
role in governing stem cell pluripotency30. In the adult spinal
cord, neural stem cells have been reported to reside close to the
central canal—in the ependymal layer31,32, subependymally33 or
in the white matter parenchyma34. In mice treated daily with
NADþ, the ependymal cell population showed signiﬁcant Ki67
immunoreactivity indicating ependymal proliferation when
compared with mice treated with placebo solution (Fig. 1j).
Ependymal cells were also strongly immunoreactive for neural
stem cell marker Musashi upon NADþ treatment when
compared with the respective control (Fig. 1k). Increased Ki67
and Musashi labelling were also observed subependymally and
in the outer white matter in NADþ-treated spinal cords
(Supplementary Fig. 1). Collectively, these results indicate that
NADþ blocks EAE progression by protecting against myelin
and axonal damage, and more importantly, that NADþ
reverses EAE progression by promoting myelin and axonal
regeneration.
EAE is a well-established mouse model that mimics many
important features of MS in humans including the immune
response. It is well established that Th1 and Th17 CD4þ cells
play a critical role in the pathogenesis of EAE, and the
transcription factor T-bet has been shown to play a critical role
in controlling Th1/Th17-mediated autoimmunity12. In contrast,
Tregs and IL-10 have been shown to play a major role in
protection against and recovery from EAE35. Our results
demonstrate that NADþ acts on the central nervous system
(CNS) by promoting myelin and axonal regeneration. However,
its role on the immune response in EAE remains unknown. Thus,
we next investigated whether NADþ treatment protected against
EAE by modifying the systemic immune response. Consistent
with a previous report27, we found that NADþ treatment
reduced the number of CD4þCD25þFoxp3þ cells (Fig. 2a).
Furthermore, although mice treated with NADþ were resistant
to EAE, we found that NADþ promoted a robust Th17 and Th1
systemic response (Fig. 2a). These ﬁndings were unexpected as
Th1 and Th17 cells are known to play a critical role in the
development of EAE. However, increasing evidence indicates that
in the presence of TGF-b1, Th17 cells are non-pathogenic and it
has been shown that TGF-b1 inhibits T-bet expression, a
transcription factor that regulates Th1/Th17-mediated
autoimmunity23,36. IL-10 has been shown to protect against
EAE and more importantly Th1 IFN-g-producing cells that co-
express IL-10 have been reported to display immunosuppressive
properties21,22,35,37. Thus, we further investigated Th1 and Th17
responses associated with NADþ. Flow cytometry results
indicated that NADþ treatment enhanced IL-10 and TGF-b by
Th1 and Th17 cells, respectively (Fig. 2a and Supplementary
Fig. 2). As control group, CD4þ T cells were isolated from naı ¨ve
mice and treated with PMA/ionomycin. As shown in
Supplementary Fig. 3, naı ¨ve CD4þ T cells did not have any
cytokine increase. Furthermore, granulocyte–macrophage colony-
stimulating factor (GM-CSF), TGF-b3 and IL-23 have been
shown to play a critical role in Th17 pathogenicity23,38,39. Our
results indicated that NADþ treatment reduced GM-CSF
expression by CD4þIL-17Aþ-producing cells, whereas IL-23R
expression was increased when compared with the control group
(Fig. 2a). However, ELISA results indicated that only TGF-b1 was
increased systemically, no differences in GM-CSF, TGF-b3 and
IL-23 were noted between the group of mice that was treated with
NADþ treatment and the control group (Supplementary Fig. 4).
Furthermore, to assess the level of inﬂammation in the spinal
cord, IFN-g and IL-17A mRNA levels in the spinal cord were
quantiﬁed by real-time PCR. In contrast to the control group, we
could not detect IFN-g or IL-17A mRNA in the spinal cord of
NADþ-treated mice (Fig. 2b). These ﬁndings suggest that
NADþ promotes homeostasis, despite the reduced frequency of
CD4þCD25þFoxp3þ Tregs, by promoting immunosuppressive
Th1 and Th17 cells. Therefore, we next sought to test whether
NADþ protective properties were mediated in part via IL-10
production. Consistent with a previous report35, our results
indicated that IL-10 /  mice were very susceptible to EAE when
compared with their wild-type (WT) counterparts (Fig. 2c).
Interestingly, NADþ did not confer protection against EAE to
MOG-immunized IL-10 /  mice (Fig. 2c). Of note, NADþ
treatment of mice did not affect the absolute number of
circulating lymphocytes in the blood or spleen (Fig. 2d). Taken
together, our results suggest that NADþ treatment alters the
systemic immune response associated with EAE and induces
homeostasis by inducing IL-10 and TGF-b1 production by Th1
and Th17 cells, respectively.
NADþ regulates CD4þ T-cell apoptosis and differentiation.
Although NADþ has been previously shown to regulate T-cell
death and cytokine production27,28,40–42, its role in T-cell
differentiation remains unknown. Our in vivo ﬁndings indicate
that NADþ alters the systemic immune response in EAE.
Therefore, we next sought to dissect the effect of NADþ on
CD4þ T-cell death and differentiation in vitro under Th0, Th1,
Th2, Th17 and induced regulatory T cells (iTreg) polarizing
conditions. To assess the role of NADþ on CD4þ T-cell
death, naı ¨ve CD4þ T cells were isolated from spleens of 5C.C7
Rag2 /  mice, and cultured under Th0, Th1, Th2, Th17 or
iTreg polarizing conditions and in the presence of increasing
concentrations of NADþ. After 4 days of culture, the toxicity of
NADþ was assessed by quantiﬁcation of apoptotic cells using
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Figure 2 | NADþ protects against EAE through IL-10. (a) C57BL/6 mice were subjected to EAE by MOG immunization and treated daily with
intraperitoneal injection of 60mg of NADþ or a placebo solution (PBS). After 18 days, mice were euthanized and CD4þ Tcells were isolated from spleens,
total cell number as well as frequencies of CD4þCD25þFoxp3 þ, CD4þIFNgþ, CD4þIFNgþIL-10þ, CD4þIL-23RþIL-17Aþ, CD4þIL-17AþGM-CSFþ,
CD4þIL-17Aþ TGFbþ cells were analysed by ﬂow cytometry. (b) mRNA was extracted from the spinal cord of treated NADþ and control group
animals and expression of IFN-g and IL-17A was measured by real-time PCR. (c) Disease scores of EAE in IL-10 /  (C57BL/6 background) and wild-type
(C57BL/6 background) mice treated with NADþ or a placebo solution (PBS). (d) Absolute number of lymphocytes in the blood and in the spleen (n¼8–11
per group, representative plots shown). Data derived from two independent experiments; data represent mean±s.d. *Po0.05; **Po0.01; ***Po0.001;
NS, not signiﬁcant; ND, non-detectable. Student’s t-test and Mann–Whitney U-test were used accordingly to compare between groups.
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Figure 3 | NADþ prevents differentiating CD4þ Tcell from apoptosis. Sorted naı ¨ve CD4þ Tcells were isolated from spleens of 5C.C7 Rag2 /  mice
(C57BL/6 background) and activated with a-CD3/a-CD28 antibodies only or in Th0 (recombinant IL-2 cytokine at a concentration of 50ngml 1),
Th1, Th2, Th17 or iTreg-polarizing conditions. Cells that were cultured in Th0, Th1, Th2, Th17 and iTreg polarizing conditions were stimulated with increasing
concentrations of NADþ (0, 5, 50 and 250mM). After 96h, percentage of apoptotic cells was assessed by ﬂow cytometry by caspase activity
measurements (n¼15; data derived from three independent experiments). Data represent mean±s.d. NS; not signiﬁcant; **Po0.01; ***Po0.001 as
determined by Student’s t-test, comparing the indicated groups.
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Our results show that treatment with NADþ of naı ¨ve CD4þ
T cells in Th0 conditions resulted in a signiﬁcant increase in
apoptosis when compared with cells that were treated with a
control solution (PBS; Fig. 3). These ﬁndings were consistent with
a previous study that showed increased cell death of naı ¨ve CD4þ
T cells in mice treated with NADþ (ref. 26). In contrast, CD4þ
T cells that were differentiated into Th1, Th2, Th17 and iTreg
were protected by NADþ against apoptosis, unlike cells that were
stimulated with a-CD3/a-CD28 antibodies alone or incubated
under Th0 polarizing conditions, consistent with a previous study
showing that effector/memory T cells were more resistant to cell
death in vivo26 (Fig. 3).
Furthermore, to determine the role of NADþ on CD4þ T-cell
differentiation, cytokine proﬁles of 5C.C7 Rag2 /  naı ¨ve CD4þ
T cells that were cultured in Th0, Th1, Th2, Th17 and iTreg
polarizing conditions were assessed by ﬂow cytometry and ELISA.
Flow cytometry analysis showed that in Th0 polarizing
conditions, NADþ was able to promote a dramatic increase in
CD4þIFNgþ and a modest increase in CD4þIL-4þ and CD4þ
IL-17þ cell frequencies in a dose-dependent manner (Fig. 4).
However, no change in CD4þIL-10þ cell frequencies was
observed after NADþ treatment (Fig. 4). In a similar manner, the
increased CD4þIFNgþ cell frequency was observed with ﬂow
cytometry sorted naı ¨ve CD4þCD25-CD44lowCD62Lhigh cells
from WT mice (Supplementary Fig. 5). ELISA data were in line
with ﬂow cytometry results (Supplementary Fig. 6). We next
investigated whether NADþ regulates CD4þ T-cell differentia-
tion under Th1 polarizing conditions. Flow cytometry analysis
showed that increasing concentrations of NADþ resulted in a
dramatic increase in CD4þIFNgþ cell frequencies (Fig. 5). More
importantly, the results showed that NADþ was able to promote
IL-10 production by IFN-g-producing Th1 cells in sorted naı ¨ve
CD4þ T cells from 5C.C7 Rag2 /  and WT animals
(Supplementary Fig. 5). Of note, NADþ was able to promote a
moderate increase in CD4þIL-17þ cell frequencies (Fig. 5).
ELISA results were consistent with ﬂow cytometry results
(Supplementary Fig. 6).
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Figure 4 | NADþ converts naı¨ve CD4þ T cells into Th1 and Th2 as well as Th17 cells. Sorted naı ¨ve CD4þ T cells were isolated from spleens of
5C.C7 Rag2 /  mice (C57BL/6 background) and were activated with a-CD3/a-CD28 antibodies only or in Th0 non-polarizing conditions (with a-CD3/
a-CD28 and 50ngml 1 of recombinant IL-2 cytokine). Cells that were cultured with recombinant IL-2 were stimulated with increasing concentrations of
NADþ (0, 5, 50 and 250mM). After 96h, percentage of CD4þIFNgþ, CD4þIL-17Aþ, CD4þIL-4þ and CD4þIL-10þ cells were assessed by ﬂow
cytometry by gating on non-apoptotic cells. To set the gates, ﬂow cytometry dot plots were based on comparison with isotype controls, ﬂuorescence minus
one (FMO), permeabilized and unpermeabilized unstained cells (n¼15; the data derived from three independent experiments). Data represent mean±s.d.;
NS, not signiﬁcant; *Po0.05; **Po0.01; ***Po0.001 as determined by Student’s t-test, comparing the indicated groups.
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from 5C.C7 Rag2 /  mice in the presence of NADþ resulted in
a strong increase in CD4þIL-4þIL-10þ and a modest increase
in CD4þIL-4þIL-17Aþ cell frequency (Fig. 6), consistent with
IL-10 and IL-17A secretion levels (Supplementary Fig. 6). Of
note, increased cell frequency of CD4þIL-4þIL-10þ was
observed with naı ¨ve WT CD4þ cells as well (Supplementary
Fig. 5). Under Th17 polarizing conditions, addition of NADþ did
not alter T-cell differentiation (Supplementary Fig. 7) and
cytokine production levels (Supplementary Fig. 6). In contrast,
under iTreg polarizing conditions, ﬂuorescence-activated cell
sorting analysis revealed a robust increase in the frequency of
CD4þTGFbþIL-17Aþ in naı ¨ve CD4þ T cells from both 5C.C7
Rag2 /  (Supplementary Fig. 8) and WT mice (Supplementary
Fig. 5). However, we found no changes in the frequency of
CD4þIL-10þIL-17Aþ cells. ELISA ﬁndings were consistent
with ﬂow cytometry (Supplementary Fig. 6).
Although our data indicate that NADþ plays an important
role in naı ¨ve CD4þ T-cell differentiation/apoptosis, it is however
unclear how NADþ can protect against EAE 15 days after MOG
immunization when CD4þ T cells have already polarized into a
speciﬁc Th phenotype. Thus, we next investigated the impact of
NADþ on differentiated CD4þ T cells. Naı ¨ve CD4þCD25 
CD44lowCD62Lhigh T cells were cultured (0.5 106 cells) in Th1
or Th2 polarizing conditions. After 1 week, polarized Th1 and
Th2 CD4þ T cells were incubated in the presence of NADþ
during 72h, rested and re-incubated in Th1 or Th2 polarizing
conditions (Fig. 7a,b). Cell number counts indicated that after
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Figure 5 | NADþ promotes IL-10 under Th1 conditions. Sorted naı ¨ve CD4þ T cells were isolated from spleens of 5C.C7 Rag2 /  mice (C57BL/6
background) and were activated with a-CD3/a-CD28 antibodies only or in Th1 polarizing conditions (with a-CD3/a-CD28, 20ngml 1 of recombinant
IL-12, 50ngml 1 of recombinant IL-2 cytokine and 10mgml 1 of anti-IL-4). Cells in Th1 polarizing conditions were cultured in the presence of increasing
concentrations of NADþ. After 96h, percentage of CD4þIFNgþIL-10þ and CD4þ IFNgþIL-17Aþ cells was measured by ﬂow cytometry by gating on
non-apoptotic CD4þ cells. To set the gates, ﬂow cytometry dot plots were based on comparison with isotype controls, ﬂuorescence minus one (FMO),
permeabilized and unpermeabilized unstained cells (n¼15; the data derived from three independent experiments). Data represent mean±s.d. NS, not
signiﬁcant *Po0.05; **Po0.01; ***Po0.001 as determined by Student’s t-test, comparing the indicated groups.
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Figure 6 | NADþ promotes IL-10 and IL-17A in Th2 polarizing conditions. Sorted naı ¨ve CD4þ T cells were isolated from spleens of 5C.C7 Rag2 / 
mice (C57BL/6 background) and were activated with a-CD3/a-CD28 antibodies only or in Th2 polarizing conditions (with a-CD3/a-CD28, 20ngml 1 of
recombinant IL-4, 50ngml 1 of recombinant IL-2, 10mgml 1 of anti-IL-12 and anti-IFN-g antibodies). Cells in Th2 polarizing conditions were cultured in
the presence of increasing concentrations of NADþ. After 96h, percentage of CD4þIL-4þIL-10þ and CD4þIL-4þIL-17Aþ cells was measured by ﬂow
cytometry by gating on non-apoptotic CD4þ cells. To set the gates, ﬂow cytometry dot plots were based on comparison with isotype controls,
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Data represent mean±s.d. NS, not signiﬁcant. *Po0.05; **Po0.01; ***Po0.001 as determined by Student’s t-test, comparing the indicated groups.
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Figure 7 | NADþ does not induce cell death. Sorted naı ¨ve CD4þ Tcells were isolated from spleens of wild-type C57BL/6 mice and cultured (0.5 106
cells per well) in Th1 (with a-CD3/a-CD28, 50ngml 1 of recombinant IL-12, 50ngml 1 of recombinant IL-2 cytokine and 10mgml 1 of anti-IL-4; a) and
Th2 (with a-CD3/a-CD28, 50ngml 1 of recombinant IL-4, 50ngml 1 of recombinant IL-2, 10mgml 1 of anti-IL-12 and anti-IFN-g antibodies; b)
polarizing conditions for 1 week, washed and followed by and incubation period of 72h with NADþ (100mM). Cells were then rested for 72h and a 2d Th1
or Th2 stimulation was performed. After 10 days, total cell numbers and frequencies of CD4þIFNgþ and CD4þIL-4þIL-10þ cells were measured by ﬂow
cytometry by gaiting on CD4þ T cells; cell proliferation was assessed by cell counting after each incubation period (n¼10; the data derived from two
independent experiments). Data represent mean±s.d. NS, not signiﬁcant. *Po0.05; **Po0.01; ***Po0.001 as determined by Student’s t-test, comparing
the indicated groups.
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and 3.5 106 cells in Th1 and Th2 polarizing conditions,
respectively (Fig. 7a,b). More importantly, when incubated in
the presence of NADþ for only 72h, Th1 and Th2 polarized cells
proliferated dramatically and the number of Th1 (2 106 cells)
and Th2 (3.5 106 cells) CD4þ cells increased signiﬁcantly
(46 106 for Th1 cells and 48 106 for Th2 cells). Although
NADþ promoted Th1 and Th2 cell proliferation, ﬂow cytometry
analysis (Fig. 7a,b) indicated that NADþ reduced dramatically
Th1 (IFN-g) and Th2 (IL-4 and IL-10) cytokine expression levels
as shown by frequency and total number of cells. To further
assess how NADþ altered CD4þ T-cell differentiation, Th1 and
Th2 cultured in the presence of NADþ were rested in media for
72h and re-stimulated in Th1 or Th2 polarizing conditions. After
10 days of culture, only 35% of CD4þ T cells were able to
produce IFN-g after Th1 re-stimulation (Fig. 7a). Similarly, upon
Th2 re-stimulation only 20% of CD4þ T cells were able to
produce IL-10. More importantly, CD4þ T cells were not able to
produce IL-4 even 10 days after Th2 re-stimulation (Fig. 7b). Of
note, after only 1 week and in similar Th1 or Th2 polarizing
conditions, more than 90% of CD4þ T cells were IFNgþ or
IL4þIL10þ, respectively. Collectively, these results demonstrate
that NADþ alters CD4þ T-cell apoptosis/proliferation and
differentiation in polarized CD4þ T cells and suggest that
NADþ may reverse the diseases progression by altering
differentiated CD4þ T cells. Moreover, the fact that NADþ
induces a robust cytokine production in naı ¨ve CD4þ T cells but
blocks cytokine production in differentiated cells suggests that
NADþ regulates CD4þ T-cell differentiation through an
alternative pathway that is distinct from the classical cytokine
pathway4,16,44–47.
NADþ signals and protects against EAE via Tph1. Our ﬁndings
clearly demonstrate that NADþ is able to alter CD4þ T-cell
differentiation in vitro and in vivo. More importantly, in vitro
results indicated that NADþ is able to override Th1, Th2 and
iTreg, but not Th17 polarizing conditions. Therefore, we sought
to proﬁle NADþ-induced perturbations in gene expression
proﬁle of Th0, Th1, Th2 and iTreg polarized cells. Although
increasing concentrations of NADþ promoted IFN-g-producing
cells in a dose-dependent manner in Th0 and Th1 polarizing
conditions, the results indicated that gene expression of T-bet, the
master regulator of Th1 development44,47, was reduced
(Supplementary Fig. 9). Of note, no changes in the expression
level of master regulators of Th2 (GATA3, STAT5a, STAT6)o r
Th17 (RORgt) were observed under Th0 polarizing conditions
(Supplementary Fig. 9). Furthermore, a dramatic decrease
(410-fold) in expression of GATA3, a transcription factor that
regulates Th2 cell differentiation, occurred under Th2 polarizing
conditions. More importantly, in the presence of NADþ, Foxp3,
the master regulator of Tregs development was not detected
under iTreg polarizing conditions (Supplementary Fig. 9).
Collectively, these ﬁndings suggest that NADþ inhibits the
expression of well-established master regulators of CD4þ T-cell
development and may induce CD4þ T-cell differentiation
through an alternative, unconventional pathway. Therefore, to
identify potential molecules involved in NADþ-mediated CD4þ
T-cell regulation, genome-wide gene expression proﬁles were
assessed by microarray analysis. Interestingly, Tph1, a gene
encoding for an enzyme that is mostly described as a mast cell
product48, was found among the top 20 upregulated genes in Th0,
Th1, Th2 and iTreg-polarized cells (Supplementary Fig. 10a).
Tph1 upregulation was conﬁrmed by real-time PCR in naı ¨ve
CD4þ T cells isolated from both, WT and 5C.C7 Rag2 /  mice
(Supplementary Fig. 10b). Similar to naı ¨ve CD4þ T cells that
were cultured under Th0, Th1, Th2 and iTreg polarizing
conditions with NADþ, polarized Th1 and Th2 CD4þ T cells
had a decreased mRNA levels of T-bet and GATA3, whereas Tph1
was dramatically increased (Supplementary Fig. 11). Although
RORgt expression was reduced in Th17 polarizing conditions in
the presence of 50 and 250mM of NADþ, the decrease was
signiﬁcant only for the latter concentration (Supplementary
Fig. 9). Furthermore, Ingenuity Pathway Analysis predicted
signiﬁcant perturbations by NADþ of other pathways
involved in T-cell differentiation, IL-17 and IL-10 signalling
(Supplementary Table 1).
Because Tph1 has recently been reported to prevent allograft
rejection and EAE48, we interrogated its involvement in vivo in
mediating the protection from EAE and regulation of CD4þ
T-cell differentiation by NADþ. Mice were subjected to EAE and
were treated daily with PBS or NADþ. Half of the animals in
each group also received p-chlorophenylalanine, a speciﬁc
inhibitor of Tph1. Onset of clinical signs of EAE in mice
immunized with MOG peptide and treated with a placebo
solution appeared after 11 days (Fig. 8a). Similar to the results
described above (Fig. 1a and Supplementary Movie 1d and f),
mice treated with NADþ were protected from EAE (Fig. 8a).
However, when NADþ-treated mice were administered the Tph1
inhibitor, onset of clinical signs of EAE appeared after 12 days
(Fig. 8a). Furthermore, on day 12 after MOG immunization, mice
treated with NADþ and p-chlorophenylalanine exhibited more
severe clinical signs of EAE than did immunized mice that
were treated with a placebo solution (Fig. 8a). Mice treated with
Tph1 inhibitor exhibited hindlimb paralysis and became
rapidly lethargic. Flow cytometry showed that the combination
of NADþ treatment with Tph1 inhibition caused a systemic
reduction in the number of CD4þIL-17Aþ and CD4þ
IL-10þIFNgþ and CD4þCD25þFoxp3þ cells (Fig. 8b).
Collectively, these results indicate that Tph1 plays a critical role
in NADþ protective properties against EAE and CD4þ T helper
cell and differentiation.
NADþ protects against EAE through IL-10 and Tr1 cells.I ti s
well established that Th1 IL-10-producing cells are robust
immunosuppressive cells that promote homeostasis20,22,37 and we
found that NADþ induces IL-10 production by Th1 cells in vitro
and in vivo. Thus, to investigate whether NADþ protective
properties were mediated through IL-10 production by Th1 cells,
naı ¨ve CD4þCD25 CD44lowCD62Lhigh T cells were obtained by
cell sorting and cultured during 4 days in Th1 polarizing
conditions in the presence of NADþ (250mM) or vehicle (PBS)
and used in an adoptive transfer experiment. After 4 days of
culture, cells were collected and injected intravenously (2 106
cells per injection) at days 3, 6 and 9 in WT mice that were
subjected to EAE. Similar to our previous results, mice treated
with NADþ were protected against EAE, whereas mice treated
with PBS and mice that received CD4þ T cells that were cultured
in the presence of a placebo solution did develop severe EAE with
clinical onset at day 11 (Fig. 8c). In contrast, mice that received
CD4þ T cells that were cultured in the presence of NADþ had a
signiﬁcant delayed clinical onset (day 13) and developed a less
severe EAE than the control groups (Fig. 8c). In addition, our
data indicate that NADþ promotes IL-10 production by Th1
cells through Tph1. Thus, to assess the role of Tph1 in IL-10
production by Th1 cells and its role in NADþ mediated
protective properties, an additional group of mice received
intravenous injections of CD4þ T cells that were previously
cultured with NADþ (250mM) and Tph1 inhibitor (200mM).
Similar to mice that received CD4þ T cells that were cultured in
the presence of a placebo solution did develop severe EAE with
clinical onset at day 11 (Fig. 8c). Taken together, these results
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6101
10 NATURE COMMUNICATIONS|5:5101|DOI: 10.1038/ncomms6101|www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.indicate that NADþ protective properties are mediated via
IL-10- and Th1-IL-10-producing cells and that Tph1 signalling
pathway plays an important role.
NADþ enhances IFN-c production independently of T-bet.
Our previous results indicated that NADþ overrides the
cytokine environment and alters CD4þ T-cell differentiation.
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Figure 8 | NADþ regulates CD4þ T-cell differentiation through Tph1. (a) Behavioural scores of EAE in wild-type C57BL/6 mice treated either with
intraperitoneal injection of 60mg of NADþ or a placebo solution (PBS). An additional group of mice was treated with intraperitoneal injections of NADþ
and p-chlorophenylalanin (Tph1 inhibitor). As a control group, wild-type mice were treated with Tph1 inhibitor alone (n¼5 per group). (b) CD4þ Tcells
were isolated from spleens 13 days after EAE induction and CD4þ frequencies of CD25þFoxp3þ, IL-17Aþ, IFNgþ and IFNgþIL-10þ cells were analysed
by ﬂow cytometry. (c) Behavioural scores of EAE in wild-type mice (C57BL/6 background) treated at days 3, 6 and 9 with intravenous injections of sorted
naı ¨ve CD4þCD25þCD44lowCD62Lhigh T cells (2 106 cells) that were cultured during 4 days in Th1 polarizing conditions in the presence of NADþ
(250mM) or a placebo solution (PBS). As control groups, wild-type mice were subjected to EAE and treated with NADþ (60mg) or PBS intravenously at
days 3, 6 and 9 (n¼8–11 per group). Data derived from two independent experiments; data represent mean±s.d. *Po0.05; **Po0.01; ***Po0.001
signiﬁcant as determined by Student’s t-test and Mann–Whitney U-test were used accordingly to compare between groups. i.p., intraperitoneal; i.v.
intravenous.
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Figure 9 | NADþ promotes IFN-c independently of the master regulator T-bet. Naı ¨ve CD4þ Tcells were isolated from wild-type and T-bet /  mice
(C57Bl/6 background) and cultured in Th1 polarizing condition (with a-CD3/a-CD28, 50ngml 1 of recombinant IL-12, 50ngml 1 of recombinant
IL-2 cytokine and 10mgml 1 of anti-IL-4) in the presence of NADþ or a placebo solution (PBS). After 1 week, CD4þIFNgþ and CD4þIFNgþIL-10þ
cells were measured by ﬂow cytometry by gating on CD4þ T cells (n¼10; the data derived from two independent experiments). Data represent
mean±s.d. NS, not signiﬁcant. ***Po0.001 as determined by Student’s t-test, comparing the indicated groups.
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was able to promote IFN-g production. In addition, we have
shown that NADþ inhibits cytokine production of polarized Th1
and Th2 CD4þ T cells and inhibits the expression of several
major transcription factors that have been shown to play a central
role in CD4þ T-cell differentiation such as T-bet, GATA3 and
Foxp3 (refs 44,45,49). In contrast, microarray analysis and real-
time PCR results showed an increased Tph1 mRNA levels
suggesting that NADþ regulates CD4þ T-cell differentiation
through Tph1 and more importantly independently of well-
established transcription factors. Thus, we next investigated
whether NADþ was able to regulate CD4þ T-cell differentiation
and promote cytokine production in the absence of major
transcription factors. Naı ¨ve CD4þCD25 CD44lowCD62Lhigh
T cells were isolated from WT and T-bet /  mice and
cultured in Th1 polarizing condition in the presence of NADþ
or a placebo solution (PBS). After 1 week, cells were analysed by
ﬂow cytometry. As shown in Fig. 9, NADþ induced a very robust
IFN-g production by WT naı ¨ve CD4þ T cells (B73%) cultured
in Th1 polarizing conditions when compared with the control
group of WT naı ¨ve CD4þ T cells that were cultured in Th1
polarizing conditions and PBS (B25%). Furthermore, NADþ
treatment of naı ¨ve CD4þ T cells isolated from T-bet /  mice
resulted in a dramatic increase of CD4þIFNgþ cells (B58%)
when compared with Th1 polarizing conditions (B8%).
More importantly, B58% of T-bet / CD4þ T cells were able
to produce IFN-g, whereas only B25% of WT CD4þ
T cells were able to produce IFNg in Th1 polarizing conditions
(Fig. 9). Taken together, these results demonstrate that NADþ is
a robust IFN-g inducer and more importantly that NADþ reg-
ulates cytokine production independently of the classical tran-
scription factors.
Discussion
In the present work, we report that NADþ is able to regulate
CD4þ T-cell differentiation (Fig. 10). In addition, our data
indicate that NADþ promotes a robust systemic IL-10 and
TGF-b1 production by Th1 and Th17 cells, respectively. IL-10
and TGF-b1 are two prominent immunosuppressive cytokines
that were shown to protect from EAE35. The central role of IL-10
in NADþ-mediated protection against EAE was demonstrated
when IL-10 /  mice treated with NADþ and subjected to EAE
developed severe clinical symptoms. More importantly,
Th1 cells that co-express IL-10 have been shown to have
immunosuppressive properties and to prevent from exaggerated
immune responses and concomitant tissue damage. Because of
their anti-inﬂammatory properties, IL-10-producing Th1 cells
were termed Tr1 cells22. Here we show that adoptive transfer of
CD4þ T cells that were differentiated in vitro under Th1
polarizing conditions in the presence of NADþ signiﬁcantly
delayed the clinical onset and reduced the severity of the disease.
These ﬁndings are in line with previous studies that have shown
that IL-10 production by IFN-g-producing Th1 cells can prevent
tissue damage and autoimmune diseases21,37. Nevertheless, mice
that received CD4þ T cells that were differentiated in vitro under
Th1 polarizing conditions in the presence of NADþ still
developed mild EAE. A recent study showed that in the
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well known that TGF-b1 is a robust immunosuppressive
cytokine50. Thus, we cannot rule out that the increased level of
TGF-b1 by Th17 cells following NADþ treatment may attenuate
Th17 pathogenicity and/or promote homeostasis. In addition,
IL-23, TGF-b3 and GM-CSF have been shown to play a critical
role in Th17 pathogenicity and EAE23,38. In our study, we could
not detect differences in IL-23, TGF-b3 and GM-CSF systemic
levels between the NADþ-treated mice and the control group.
Although ﬂow cytometry analysis showed that NADþ treatment
resulted in a modest decrease of GM-CSF production by
CD4þIL-17Aþ cells and an increased expression of IL-23R, we
do not believe that IL-23, TGF-b3 or GM-CSF play a role in
NADþ signalling machinery.
T-bet has been shown to play a critical role in controlling
Th1/Th17-mediated autoimmunity12. T-bet-deﬁcient mice have
been shown to be resistant to autoimmunity, whereas IFN-g-,
IFN-g receptor- and IL-17-deﬁcient mice remain susceptible
to EAE12. Our study demonstrates that NADþ reduces the
expression level of T-bet under Th0, Th1 polarizing conditions
and in differentiated Th1 cells, suggesting that NADþ may
protect against EAE by inhibiting T-bet expression and thus
altering Th1/Th17-mediated autoimmunity. Bruzzone et al. have
shown that depletion of NADþ using FK866, an inhibitor of a
key enzyme for NADþ biosynthesis, reduced clinical symptoms
in EAE. The study showed that NADþ depletion with FK866
spared resting T lymphocytes and targeted speciﬁcally activated
T lymphocytes resulting in increased apoptosis, reduced
proliferation and cytokine production25. In contrast, in our
study, we showed that treatment with NADþ-protected activated
CD4þ T cells from apoptosis and instead regulated their
differentiation. Thus, we believe that NADþ depletion by
FK866 reduced EAE clinical symptoms mainly by inducing cell
death of activated cells, whereas treatment with NADþ protected
against EAE by inducing homeostasis and by promoting myelin
regeneration and neuroregeneration.
Furthermore, NADþ was able not only to block but also to
reverse EAE progression by restoring myelin and favouring
axonal regeneration, suggesting that NADþ may promote this
process by inhibiting the inﬂammatory response or might act
directly on other pathways involved in the CNS in particular in
maintaining pluripotency30. Initially, NADþ was used as a
therapeutic agent to treat schizophrenic patients51,52. Although a
more recent study suggested that NADþ might prevent from
axonal degeneration24, the direct impact of NADþ on the CNS
remains unclear and warrants further investigation. Of note, low
dose of NADþ such as 10mg was effective in protecting against
EAE. According to many reports and the Food and Drug
Administration53 guidelines, injection of 10mg in our animal
model corresponds to a dose of 1.6g for an individual of 70kg,
which is a reasonable daily dose for patients.
Moreover, our study has uncovered a new role of NADþ in
CD4þ T-cell differentiation. Under Th1 polarizing conditions
and in the presence of NADþ, CD4þ T helper cells were able to
rapidly secrete high amounts of IL-10, conventionally considered
as a Th2 cytokine. Interestingly, previous studies have shown that
Th1 cells are able to produce IL-10 in culture when provided
longer incubation time (2–5 weeks) and high T-cell antigen
receptor stimulation54 or chronic Th1 activation20. In our hands,
NADþ was able to induce IL-10 secretion by IFN-g-producing
Th1 cells within hours without high T-cell antigen receptor
stimulation, indicating that NADþ is a robust inducer. Although
it is well accepted that IL-4 inhibits IL-17A production under Th2
polarizing conditions5,7,15, Wang et al. have described a CD4þ
Th2 subset that co-produces IL-4 and IL-17A and have shown
that these cells were the main cause of lung inﬂammation in the
chronic stage of asthma55. However, the mechanisms that
promote CD4þIL-4þIL-17Aþ cell development remain
unknown. The mechanism of action of NADþ was conﬁrmed,
in vitro, with its capacity to convert iTregs into Th17 cells even in
the presence of IL-2, a cytokine that is known to prevent Th17
lineage commitment56,57. More importantly, T-bet and GATA3,
two transcription factors that regulate CD4þ T cell Th1/Th2 fate
decision were downregulated by NADþ, whereas Foxp3, the
master regulator of Tregs, was not detected, suggesting that
NADþ regulates CD4þ T-cell differentiation through an
alternative pathway. This alternative pathway was demonstrated
using naı ¨ve T-bet / CD4þ T cells. In the presence of NADþ,
B58% of T-bet / CD4þ T cells were able to produce IFN-g,
whereas only B8% were able to produce IFN-g in solely Th1
polarizing conditions. More importantly, only 25% of WT CD4þ
T cells were IFN-g in Th1 polarizing conditions, indicating that
NADþ not only promotes IFN-g production independently of
T-bet but also underscoring NADþ as a more potent IFN-g
inducer than Th1 polarizing conditions. In parallel to the
decreased expression of T-bet, GATA3 and Foxp3, NADþ
induced a robust increase in Tph1 expression by CD4þ T
helper cells under Th polarizing conditions, suggesting a central
role in NADþ-mediated CD4þ T-cell differentiation. Indeed,
treatment with a Tph1 inhibitor dampened the systemic IL-17A
and IL-10/IFN-g responses observed after NADþ administration,
conﬁrming that Tph1 is critical in NADþ-mediated T-cell
differentiation. Moreover, mice treated with NADþ and Tph1
inhibitor simultaneously developed a more severe EAE than mice
that were subjected to MOG immunization and treated with a
placebo solution, indicating that Tph1 signalling pathway plays a
critical role in NADþ protective properties against EAE. These
ﬁndings were in line with a previous study that showed that
Tph1-deﬁcient mice were more susceptible to EAE48. In addition,
the combination of NADþ and Tph1 inhibitor developed severe
lethargy 13 days following MOG immunization and animals had
to be euthanized. The cause of death was not due to MOG
immunization but was most likely the result of heart failure and
breathing difﬁculties. Indeed, Tph1 inhibition has been shown to
promote serotonin depletion, a crucial neurotransmitter58,
causing breathing difﬁculties and inducing heart failure59.
In conclusion, our study underscores NADþ as a major
regulator of CD4þ T-cell differentiation that signals through a
novel pathway that is distinct from the classical pathway
described almost three decades ago2–4. Furthermore, our study
demonstrates that NADþ acts independently of the major
transcription factors described16,44–47,49 and signals through
Tph1 enzymatic pathway. On a clinical aspect, our study
unravels the therapeutic potential of NADþ as a homeostatic
agent in a myriad of diseases. The unique property of NADþ
in inducing homeostasis that is not mediated by
CD4þCD25þFoxp3þ regulatory T cells may beneﬁt
immunodeﬁcient patients that result from mutations in the
Foxp3 gene60. In addition to its antitumour properties27, NADþ
may be the ideal molecule to treat autoimmune diseases such as
MS, type 1 diabetes and inﬂammatory bowel disease in which
IL-10 has been shown to play a central role61. Moreover,
NADþ homeostatic properties could be used as therapy beyond
autoimmune diseases, including acute and chronic inﬂammatory
diseases62.
Methods
Animals. Eight- to ten-week old female B10.A-Rag2tm1FwaH2-T18aTg or
wild-type (WT) mice on a C57BL/6 background were purchased from Taconic.
B6.129P2-IL10tm1Cgn/J and B6.129S6-Tbx21tm1Glm/J mice were purchased from
the Jackson Laboratory. Animal use and care were in accordance with the
National Institutes of Health and Institutional Animal Care and Use Committee
guidelines.
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5- to 10-week-old 5C.C7 Rag2 / , T-bet /  or WT mice. Depletion of
non-CD4þ T cells was done using biotin-conjugated monoclonal anti-mouse
antibodies against CD8a, CD11b, CD45R, CD49b, Ter-119 and anti-biotin
magnetic beads (Miltenyi Biotec). Cells were further sorted using a-CD4-PE and
a-PE magnetic beads (Miltenyi Biotec) and CD4þCD25-CD44lowCD62Lhigh
(all eBioscience) cells were sorted by ﬂow cytometry. All antibodies were used
at a concentration of 1–2mg per 1 106 cells. Purities of CD4þCD25-
CD44lowCD62Lhigh T cells after isolation were 499.2%.
Cell culture. Isolated CD4þ T cells were cultured in 24-well ﬂat bottom plates
(0.5 106 cells per well) in 0.5ml of complete RPMI 1640 media (supplemented
with 10% FCS, 200mM L-glutamine, 100Uml 1 penicillin/streptomycin and
5 10-5M 2-mercaptoethanol (RP-10) in the presence of 10mgml 1 plate-bound
anti-mouse a-CD3 (17A2) and 2mgml 1 soluble a-CD28 (37.51) in addition to
50ngml 1 recombinant mouse IL-2 (all eBioscience). NADþ (Sigma-Aldrich)
was diluted in PBS and added as indicated. Cells were cultured in polarizing Th1
(50ngml 1 of recombinant IL-12 and 10mgml 1 of anti-IL-4), Th2 (50ngml 1
of recombinant IL-4, 10mgml 1 of anti-IFN-g), Th17 (10ngml 1 of recombi-
nant TGF-b, 100ngml 1 of recombinant IL-6, 10mgml 1 of anti-IFN-g and
10mgml 1 of anti-IL4) or iTreg (10ngml 1 of recombinant TGF-b,1 0mgml 1
of anti-IFN-g and 10mgml 1 of anti-IL4) conditions. All recombinant cytokines
and antibodies were purchased from eBioscience except recombinant TGF-b
cytokine (R&D Systems). After 96h of culture supernatants and cells were collected
and analysed by ELISA and ﬂow cytometry, respectively.
To investigate the impact of NADþ on polarized CD4þ T cells, naı ¨ve CD4þ
T cells were isolated and cultured in Th1 or Th2 polarizing conditions as described
above. After 1 week, cells were washed and incubated in the presence of NADþ
(100mM) or PBS. After 72h, cells were rested during an additional 72h and
re-stimulated with Th1 or Th2 polarizing conditions. After 10 days, cells were
stained and analysed by ﬂow cytometry.
Flow cytometry. Fluorescence-labelled anti-mouse a-CD4 (GK1.5), a-CD25
(PC61), a-IFN-g (XMG1.2) and unlabelled a-CD16/CD32 (2.4G2) antibodies were
obtained from BD Biosciences. Fluorescence-labelled anti-mouse a-IL-4 (FJK-16s),
a-IL-10 (JES5-16E3), a-IL-17A (eBio17B7), anti-GM-CSF (MP1-22E9), anti-Foxp3
(FJK-16s) and anti-TGFb1 (TW7-16B4) were obtained from eBioscience. Anti-
mouse anti-IL23R (753317) was purchased from R&D systems. All antibodies were
used at a concentration of 2–5mg per 1 106 cells. To set the gates, ﬂow cytometry
dot plots were based on comparison with isotype controls, ﬂuorescence minus one,
permeabilized and unpermeabilized unstained cells. Intracellular staining for IL-4,
IL-10, IL-17A, IFN-g, GM-CSF and TGF-b was performed according to the
manufacturers’ protocols. Splenocytes were re-stimulated in complete media
(RPMI media containing 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin;
all from Bio Whittaker) for 4h at 37C with ionomycin, phorbol 12-myristate
13-acetate and Brefeldin A (eBioscience). Cells were ﬁxed and permeabilized using
Cytoﬁx/Cytoperm solution (BD Biosciences). Flow cytometry measurements of
single-cell suspensions for in vivo experiments were performed on a FACSCalibur
using standard procedures and data were analysed using FlowJo software (Tree
Star). Flow cytometry measurements for in vitro experiments were performed on
MoFlo Astrios (Beckman Coulter) and data were analysed using Kaluza software
(Beckman Coulter).
Apoptosis. Apoptosis was assessed by caspase (caspase-1, -3, -4, -5, -6, -7, -8
and -9) activity measurements. Caspases activities were determined by ﬂow
cytometry using FAM-ﬂuorochrome inhibitor of caspases (FLICA) Poly Caspase
Assay Kit (Immunochemistry Technologies) all dilutions and staining protocols
were performed according to the manufacturer’s instruction. Brieﬂy, after 96h of
culture in Th0, Th1, Th2, Th17 or iTreg polarizing condition, sorted naı ¨ve CD4þ
T cells were incubated with a 30  FLICA solution for 1h at 37C. Following
incubation time, cells were washed with apoptosis wash buffer included in the kit.
Cells were then analysed on a MoFlo ﬂow cytometer (Beckman Coulter), gating on
the live cells and measuring the ﬂuorescence due to the presence of FAM-FLICA
bound to several caspases (caspase-1, -3, -4, -5, -6, -7, -8 and -9).
ELISA. Mouse IL-4, IL-10, IL-17A, IFN-g, GM-CSF, IL-23 and TGF-b1 were
measured using commercial kits (eBioscience). Mouse TGF-b3 was measured using
commercial kit (Catalog# SEB949Mu) from Cloud-clone. Brieﬂy, ELISA plates
were coated with 100ml of anti-cytokine capture antibody at 4C overnight. Plates
were then washed  5 with 0.05% PBS-Tween (PBST) and coated for 1h with the
blocking buffer provided by the manufacturer. Samples or standards were added in
duplicates (100ml per well) and incubated at 4C overnight. Wells were washed
 5 with PBST and incubated with 100ml of anti-cytokine detection antibody at
4C overnight. Wells were then washed  5 with PBST and incubated with 100ml
of avidin-HRP at room temperature for 30min. Thereafter, wells were washed  7
with PBST and incubated with 100ml per well of a substrate. The reaction was
stopped after 15min with 1M H2SO4 and absorbance was measured using a
multiplate microplate ﬂuorescence reader (Synergy HT, Biotek) at 405nm.
RNA extraction, real-time PCR and microarray analyses. CD4þ T cells were
isolated from WT mice (isolated with anti-biotin magnetic beads (Miltenyi Biotec),
cultured in Th0, Th1, Th2 and iTreg polarizing conditions and used for microarray
analyses and real-time PCR reactions. CD4þ T cells from 5C.C7 Rag2 /  mice
were cultured in Th0, Th1, Th2 and iTreg polarizing conditions and used exclu-
sively for real-time PCR reactions. After 96h of culture, cells were collected and
RNA was extracted using the RNAqueous extraction kit according to the manu-
facturer’s protocols (Applied Biosystems). Brieﬂy, cells were homogenized in lysis
buffer (total volume of 0.5ml) and passed through a column. After successive
washes, RNA was eluted. For real-time PCR reactions, T-bet (Mm00450960_m1),
GATA3 (Mm00484683_m1), STAT5a (Mm03053818_s1), STAT6
(Mm00447411_m1), RORgt (Mm01261022_m1), Foxp3 (Mm00475162_m1)
and tryptophan hydroxylase-1 (Tph1) (Mm00493794_m1) measurements were
performed with Taqman primers and probes from Applied Biosystems. The
housekeeping gene GAPDH (Mm99999915_g1) was used as control. Microarray
analyses were performed using affymetrix genechip. Brieﬂy, the cDNA (10mg) was
fragmented and labelled and then hybridized to a GeneChip Mouse Genome 430
2.1 array (Affymetrix). Affymetrix microarray data analysis was performed using
Partek Genomics Suite software (Partek Inc.). Default settings were used for
quantile normalization and RMA summarization. The samples were grouped and
statistics were applied using the analysis of variance model employing linear
contrast. Linear contrast was established for each pair of grouped samples for
which the analysis was appropriate. Gene lists were then created for each analysis
for downstream pathway analysis using threshold values of FDR-adjusted P-value
r0.05 and fold change Z2 and r2. The Ingenuity Pathways Analysis (Ingenuity
Systems) applications were used to generate canonical pathways associated with the
differentially expressed gene proﬁles extracted from the transcriptome data.
RNA extraction from spinal cord tissue was performed using RNAqueous
extraction kit according to the manufacturer’s protocol (Applied Biosystems).
Brieﬂy, 1mg of spinal cord tissue was homogenized in lysis buffer (total volume of
0.5ml) and passed through a column. After successive washes, RNA was eluted and
reverse transcription was performed using i-Script cDNA synthesis kit (Bio-Rad
Laboratories). PCR reactions were performed with IFN-g (Mm01168134_m1) and
IL-17A (Mm00439619_m1) Taqman primers and probes from Applied Biosystems.
Relative gene expression was determined using the housekeeping gene GAPDH
(Mm99999915_g1) as control.
EAE mouse model. EAE was induced in 8- to 10-week-old WT or IL-10 /  mice
using Hooke Labs EAE induction kit (EK-2110) according to the manufacturer’s
instructions (Hooke Laboratories Inc.). Mice were scored daily on a scale of 0–5 in
a double-blind manner with the following criteria: score 0, no signs of neurological
disease; score 1, ﬂaccid paralysis of the tail; partial or no tail muscle tone, mouse is
unable to curl tail around ﬁnger or pencil; score 2, weak hindlimb paralysis or
wobbling gait and/or impaired righting reﬂex; score 3, bilateral hindlimb paralysis,
mouse drags its hindlimbs over ﬂat surface and/or exhibits incontinence; score 4,
hind- and forelimb paralysis, mouse barely moves around; score 5, moribund
animal). For NADþ treatment, mice received a daily intraperitoneal injection
(60mg in 100ml in PBS) or a placebo solution (100ml of PBS) at the same day than
MOG immunization. Mice were killed at day 18 and single-cell suspension was
obtained from spleens for ﬂow cytometry analysis. To test whether NADþ was
able to reverse the development of EAE, another group of mice was treated daily
(for a period of 10 days) with NADþ (60mg per mouse) or a placebo solution
(PBS) 15 days after MOG immunization when mice were scored 3 with a bilateral
hindlimb paralysis. EAE disease progression was monitored. For Tph1 inhibition,
mice were subjected to MOG immunization and treated daily with NADþ.O n e
week after MOG immunization, mice received daily intraperitoneal injections
(simultaneous to NADþ)o fp-Chlorophenylalanine (1ml of a 10mM stock
solution, catalogue number 0938, Tocris Bioscience).
Adoptive transfer. Naı ¨ve sorted CD4þCD25 CD44lowCD62Lhigh cells were
cultured in Th1 polarizing in the presence of NADþ (250mM), PBS or a cocktail
of NADþ (250mM) and Tph1 inhibitor (200mM). After 4 days of culture, cells
were collected, washed and 2 106 cells were re-suspended in 100ml of PBS and
injected intravenously in mice that were subjected to EAE at days 3, 6 and 9 post
MOG-immunization.
Histology, immunohistochemistry and quantiﬁcation. Animals used to assess
EAE clinical symptoms (n¼6 per group) were killed 25 days after MOG
immunization. After transcardial perfusion with 4% paraformaldehyde, lumbar
spinal cord was isolated from the three groups of mice: (i) mice that were treated
daily with a placebo solution (PBS), (ii) mice that were treated daily with NADþ
and (iii) mice that were treated 15 days with NADþ after MOG immunization
(when mice developed hindlimb paralysis). Spinal cords from the three groups
were ﬁxed in 4% paraformaldehyde for 24h and processed for parafﬁn histology.
Histological stainings with LFB (American MasterTech Scientiﬁc Inc.) and
H&E (Sigma) were performed on 8-mm-thick transverse parafﬁn sections and
immunohistochemistry was performed on 20-mm-thick parafﬁn sections. Primary
antibodies used for immunohistochemistry were: monoclonal antibody to MBP
(SMI-94) (1:400, Millipore) and rabbit polyclonal antibody to NF 200 (1:50,
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6101 ARTICLE
NATURE COMMUNICATIONS|5:5101|DOI: 10.1038/ncomms6101|www.nature.com/naturecommunications 15
& 2014 Macmillan Publishers Limited. All rights reserved.Sigma), Ki67 (1:30, Sigma) and Musashi (1:50, Millipore) followed by secondary
detection with Alexa Fluor conjugates (Molecular Probes). DAPI (Vector
Laboratories) was used to label nuclei. Brightﬁeld and ﬂuorescent images were
obtained from an FSX100 microscope (Olympus). The areas of demyelination were
quantiﬁed either by immunocytochemistry or immune ﬂuorescence microcopy
using ImagePro Plus 7.0 software (Media Cybernetics). For brightﬁeld immuno-
histochemistry analysis, before quantiﬁcation, each RGB image was converted into
an image representing exclusively the saturation channel, and then the segmen-
tation values established on a region of interest corresponding to the white matter
in the untreated group was applied to all sections. The results represent optical
density and area. Staining artefacts were removed manually following automatic
quantiﬁcation. Total areas measured represent three full transverse spinal cord
sections per animal for each group. For ﬂuorescence determination of NFþ area,
monochrome images were analysed by quantifying intensity values using an
automated segmentation script based on values obtained on the untreated group.
Count of absolute number of lymphocytes. C57BL/6 mice (8- to 10-week old)
were administered daily 60mg of NADþ or a placebo solution (PBS) intaper-
itoneally during 4 days. Blood and spleen were collected after 4 days of treatment.
Absolute number of lymphocytes in the blood was determined using a haemo-
cytometer (model 850 FS, Drew Scientiﬁc). To determine absolute lymphocyte
number in spleens, cells were isolated and counted with a haemocytometer, then
stained with anti-CD4þ, anti-CD3þ or anti-B220þ antibodies and percentages
were determined by ﬂow analysis.
Statistical analysis. Data are presented as the mean±s.d. Statistical analysis
compared the groups with a two-tailed Student’s t-test or Mann–Whitney test were
appropriate. Only P-values o0.05 were considered statistically signiﬁcant.
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